David Martin, PhD

Dave Martin has more than 30 years of experience advancing novel therapeutics through clinical development at both large and small biotechnology companies. His work spans therapeutic areas, including neurodegenerative disorders, oncology and nephrology.

During his 15-year tenure at Amgen, Dave was Executive Director of Renal Research and was involved in the approval of Sensipar® for secondary hyperparathyroidism. He was also instrumental in leading IND-enabling studies for a glial-derived neurotrophic growth factor for Parkinson’s disease, an interleukin-1 receptor antagonist for multiple sclerosis, and calcimimetic leads for secondary hyperparathyroidism and gastrointestinal disorders. Most recently, Dave was Senior Vice President of Nonclinical and Clinical Pharmacology at QED Therapeutics, where he was involved in the development of Truseltiq™, which was approved for cholangiocarcinoma. Previously, he was Senior Director, Nonclinical Development at Puma Biotechnology, where his work led to the approval of Nerlynx® for HER2+ breast cancer.

Dave received his PhD in Pharmacology from the Royal Veterinary School at the University of London and his BSc from North East London Polytechnic. He completed a one-year post-doctoral fellowship at Duke University Medical Center. Dave was appointed Research Assistant Professor at Duke University and held a joint position with the Veterans Administration in Durham, NC. Dave has published extensively, including 120 manuscripts, book chapters and patents.